ClinCalc Pro
Menu
ToxicologyEmergencyHaematology

DOAC overdose / reversal

Reversal of life-threatening bleeding from DOACs — idarucizumab for dabigatran, andexanet alfa or PCC for factor Xa inhibitors.

Source: BSH 2018; ESC 2021; TOXBASE/NPIS; SmPC Praxbind/Ondexxya

Step 1 of ~8
action

Identify the agent and timing

Identify exact DOAC, last dose time, dose, indication, renal/hepatic function. Co-medications (antiplatelets, NSAIDs). DOACs: • Dabigatran (direct thrombin inhibitor) → idarucizumab • Apixaban / rivaroxaban / edoxaban (factor Xa inhibitors) → andexanet alfa or 4-factor PCC ABCDE; large-bore IV access x2; group & save / cross-match; bloods: FBC, U&E, creatinine, LFTs, fibrinogen, INR (insensitive for DOACs), APTT (raised in dabigatran), thrombin time (very sensitive for dabigatran), anti-Xa level if available, lactate, VBG.

Related

Curated clinical cross-links plus same-class fallbacks.

Decision support only. Always apply local guidelines and clinical judgement.